Misonix, Inc. To Report Financial Results For The First Quarter Of Fiscal Year
2014 On Thursday, November 7, 2013
Conference call to be conducted at 4:30 pm ET
FARMINGDALE, N.Y., Nov. 4, 2013
FARMINGDALE, N.Y., Nov. 4, 2013 /PRNewswire/ --Misonix, Inc. (NASDAQ: MSON),
an international surgical device company that designs, manufactures and
markets innovative therapeutic ultrasonic products for spine surgery,
skull-based surgery, neurosurgery, wound debridement, cosmetic surgery,
laparoscopic surgery and other surgical applications, announced today that it
will report financial results for the first quarter of fiscal year 2014 ended
September 30, 2013 on Thursday, November 7, 2013. The Company has scheduled a
conference call that same day, Thursday, November 7, 2013, at 4:30 pm ET to
review the results.
Interested parties can access the conference call by dialing (877) 317-6789 or
(412) 317-6789 or can listen via a live Internet webcast, which is available
in the Investor Relations section of the Company's website at www.misonix.com.
A teleconference replay of the call will be available for three days at (877)
344-7529 or (412) 317-0088, confirmation # 10036674. A webcast replay will be
available in the Investor Relations section of the Company's website at
www.misonix.com for 30 days.
Misonix, Inc. designs, develops, manufactures and markets therapeutic
ultrasonic medical devices. Misonix's therapeutic ultrasonic platform is the
basis for several innovative medical technologies. Addressing a combined
market estimated to be in excess of $3 billion annually; Misonix's proprietary
ultrasonic medical devices are used for wound debridement, cosmetic surgery,
neurosurgery, laparoscopic surgery, and other surgical and medical
applications. Additional information is available on the Company's Web site at
Safe Harbor Statement
With the exception of historical information contained in this press release,
content herein may contain "forward looking statements" that are made pursuant
to the Safe Harbor Provisions of the Private Securities Litigation Reform Act
of 1995. These statements are based on management's current expectations and
are subject to uncertainty and changes in circumstances. Investors are
cautioned that forward-looking statements involve risks and uncertainties that
could cause actual results to differ materially from the statements made.
These factors include general economic conditions, delays and risks associated
with the performance of contracts, risks associated with international sales
and currency fluctuations, uncertainties as a result of research and
development, acceptable results from clinical studies, including publication
of results and patient/procedure data with varying levels of statistical
relevancy, risks involved in introducing and marketing new products, potential
acquisitions, consumer and industry acceptance, litigation and/or court
proceedings, including the timing and monetary requirements of such
activities, the timing of finding strategic partners and implementing such
relationships, regulatory risks including approval of pending and/or
contemplated 510(k) filings, the ability to achieve and maintain profitability
in the Company's business lines, and other factors discussed in the Company's
Annual Report on Form 10-K, subsequent Quarterly Reports on Form 10-Q and
Current Reports on Form 8-K. The Company disclaims any obligation to update
its forward-looking relationships.
Misonix Contact: Investor Contact:
Richard Zaremba Joe Diaz
631-694-9555 Lytham Partners
SOURCE Misonix, Inc.
Press spacebar to pause and continue. Press esc to stop.